Acceptance in Major Peer-Reviewed Journals of two Landmark Pre-Clinical Studies

Alpha Tau Appoints Industry Veteran Peter Melnyk as Chief Commercial Officer

Alpha Tau Medical to Participate in Upcoming September Investor Conferences

Alpha Tau Medical Announces Second Quarter 2022 - Financial Results and Provides Corporate Update

Alpha Tau and MIM Software Announce Collaboration for Alpha DaRT Treatment Planning

Alpha Tau Hosting Key Opinion Leader Meeting on Alpha DaRT Clinical Trials

Alpha Tau Announces Treatment of First Prostate Cancer Patient with Alpha DaRT™

Receipt of Radioactive License to Allow Production in Main Manufacturing Floor at its Jerusalem Site

FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC

Alpha Tau Announces Resignation of Gary Leibler from its Board of Directors